biostudies-literatureUnknown3(4)Lam MA<h4>Objective</h4>We aimed to investigate the role of oxidative stress in the progression of multiple sclerosis (MS).<h4>Methods</h4>We determined by liquid chromatography-tandem mass spectrometry nonenzymatic (F2-isoprostanes) and enzymatic oxidation products of arachidonic acid (prostaglandin F2α [PGF2α]) in plasma and CSF of 45 controls (other neurologic disease [OND] with no signs of inflammation) and 62 patients with MS. Oxidation products were correlated with disease severity and validated biomarkers of inflammation (chemokine ligand 13; matrix metalloproteinase-9; osteopontin) and axonal damage (neurofilament light protein).<h4>Results</h4>Compared with OND controls, plasma concentrations of F2-isoprostanes and PGF2α were significantly lower in patients with progressive disease, andNeurology(R) neuroimmunology & neuroinflammatione256https://www.ebi.ac.uk/biostudies/studies/S-EPMC4929888biostudies-literatureAbsence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.PMC4929888Sellebjerg FTRatzer ROlsson TKhademi MLam MARomme Christensen JPiehl FStocker RMaghzal GJfalseAbsence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.<h4>Objective</h4>We aimed to investigate the role of oxidative stress in the progression of multiple sclerosis (MS).<h4>Methods</h4>We determined by liquid chromatography-tandem mass spectrometry nonenzymatic (F2-isoprostanes) and enzymatic oxidation products of arachidonic acid (prostaglandin F2α [PGF2α]) in plasma and CSF of 45 controls (other neurologic disease [OND] with no signs of inflammation) and 62 patients with MS. Oxidation products were correlated with disease severity and validated biomarkers of inflammation (chemokine ligand 13; matrix metalloproteinase-9; osteopontin) and axonal damage (neurofilament light protein).<h4>Results</h4>Compared with OND controls, plasma concentrations of F2-isoprostanes and PGF2α were significantly lower in patients with progressive disease, and2016-01-01T00:00:00Z2016 Aug2025-04-18T19:45:36.38Z2019-03-27T02:17:21ZS-EPMC49298882738650610.1212/NXI.0000000000000256